Lamivudine + nevirapine + stavudine
Pharmaceutical forms
Tablet
Country lists
ATC N/A
Composition 150 mg + 200 mg + 30 mg
Observations for this pharmaceutical form can be found on the lists:
WHO Model List of Essential Medicines
6.4.2.3. Protease inhibitors
  • Others observations:
    Fixed-dose-combinations.
PAHO Strategic Fund Medicine List
2.5. Antiretrovirals
  • No observations
Peru
6.4.2.3 Protease Inhibitors
  • No observations
Tablet (dispersible)
Country lists
ATC N/A
Composition 30 mg + 50 mg + 6 mg
Observations for this pharmaceutical form can be found on the lists:
WHO Model List of Essential Medicines
6.4.2.3. Protease inhibitors
  • This medicine is only for children.
  • Others observations:
    Fixed-dose-combinations.
PAHO Strategic Fund Medicine List
2.5. Antiretrovirals
  • Others observations:
    Limited supply options (normally, none or only one supplier identified / prequalified); may result in longer delivery times.
Tablet (dispersible)
Country lists
ATC N/A
Composition 60 mg + 100 mg + 12 mg
Observations for this pharmaceutical form can be found on the lists:
WHO Model List of Essential Medicines
6.4.2.3. Protease inhibitors
  • This medicine is only for children.
  • Others observations:
    Fixed-dose-combinations.
PAHO Strategic Fund Medicine List
2.5. Antiretrovirals
  • Others observations:
    Limited supply options (normally, none or only one supplier identified / prequalified); may result in longer delivery times.